Literature DB >> 15243755

Erythema multiforme major following docetaxel.

Christina Moisidis1, Volker Möbus.   

Abstract

OBJECTIVE: The objective was to report a severe skin reaction, erythema multiforme major, following administration of docetaxel. CASE
SUMMARY: A female patient receiving weekly docetaxel for metastatic breast cancer developed a severe skin reaction characterized by blistering target lesions on her upper and lower extremities as well as painful ulcers of her oropharynx. The diagnosis of erythema multiforme major was made and high-dose hydrocortisone began, with gradual resolution of her symptoms. DISCUSSION: The semi-synthetic taxoid docetaxel, which is increasingly being used in the treatment of breast cancer, has been associated with several adverse skin reactions, including hypersensitivity, nail pigmentation, nail onycholysis, erythrodysethesia, and scleroderma. We report the first case of erythema multiforme major (Stevens-Johnson syndrome) following docetaxel. Erythema multiforme major is a rare inflammatory skin disease associated with certain drugs (i.e., sulfonamides, non-steroidal anti-inflammatory agents, anticonvulsants). It is characterized by a distinguishing target skin lesion and ulceration of mucosal surfaces. In severe cases, systemic manifestations such as pneumonitis can also occur. Treatment involves use of moderate to high-dose corticosteroids.
SUMMARY: Clinicians using docetaxel should be aware of the variety of skin reactions that can occur, how they can be avoided and their severity reduced. Severe skin reactions such as occurred with our patient should be recognized and treated promptly in consultation with a dermatologist.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15243755     DOI: 10.1007/s00404-004-0643-9

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN: 0932-0067            Impact factor:   2.344


  8 in total

Review 1.  Dermatological adverse events with taxane chemotherapy.

Authors:  Vincent Sibaud; Nicole R Lebœuf; Henri Roche; Viswanath R Belum; Laurence Gladieff; Marion Deslandres; Marion Montastruc; Audrey Eche; Emmanuelle Vigarios; Florence Dalenc; Mario E Lacouture
Journal:  Eur J Dermatol       Date:  2016-10-01       Impact factor: 3.328

2.  Docetaxel-induced Scleroderma in A Breast Cancer Patient: A Case Report.

Authors:  Murat Özgür Kılıç; Metin Yalaza; Celal İsmail Bilgiç; Cenap Dener
Journal:  J Breast Health       Date:  2015-04-01

3.  Management of hypersensitivity to platinum- and taxane-based chemotherapy: cepo review and clinical recommendations.

Authors:  J Boulanger; J N Boursiquot; G Cournoyer; J Lemieux; M S Masse; K Almanric; M P Guay
Journal:  Curr Oncol       Date:  2014-08       Impact factor: 3.677

4.  [Lethal course after chemotherapy with docetaxel. Acute liver failure with accompanying erythema multiforme major].

Authors:  C-H Ohlmann; S Kohlmorgen; D Sahi; U Engelmann; A Heidenreich
Journal:  Urologe A       Date:  2007-10       Impact factor: 0.639

5.  Life-threatening dermatologic adverse events in oncology.

Authors:  Alyx C Rosen; Yevgeniy Balagula; Dennis W Raisch; Vishvas Garg; Beatrice Nardone; Nicole Larsen; Jennifer Sorrell; Dennis P West; Milan J Anadkat; Mario E Lacouture
Journal:  Anticancer Drugs       Date:  2014-02       Impact factor: 2.248

6.  Weekly docetaxel, zoledronic acid and estramustine in hormone-refractory prostate cancer (HRPC).

Authors:  Joseph G Kattan; Fady S Farhat; Georges Y Chahine; Fady L Nasr; Walid T Moukadem; Fariha C Younes; Nadine J Yazbeck; Marwan G Ghosn
Journal:  Invest New Drugs       Date:  2007-09-06       Impact factor: 3.850

Review 7.  Anticancer Drugs Induced Severe Adverse Cutaneous Drug Reactions: An Updated Review on the Risks Associated with Anticancer Targeted Therapy or Immunotherapies.

Authors:  Chau Yee Ng; Chun-Bing Chen; Ming-Ying Wu; Jennifer Wu; Chih-Hsun Yang; Rosaline Chung-Yee Hui; Ya-Ching Chang; Chun-Wei Lu
Journal:  J Immunol Res       Date:  2018-01-17       Impact factor: 4.818

8.  Docetaxel-Induced Stevens-Johnson Syndrome in a Patient with Metastatic Prostate Adenocarcinoma.

Authors:  Osama Diab; Dan Mcentire; Thamer Kassim; Ali Nayfeh; Abdel Rahman Dajani; Mitchell Kerfeld; Jonathon Campbell; Adbullah Alsuwaidan; Mahmoud Abu Hazeem; Maryam Gbadamosi-Akindele
Journal:  Case Rep Oncol Med       Date:  2019-01-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.